anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A self-propelling composition capable of dispensing a powder in aerosol form comprises a finely divided powder suspended in a mixture of a liquefied propellant having a b.p. less than 65 DEG  F. at atmospheric pressure and a liquid non-ionic surface-active agent. The powder should have a substantially uniform particle size not greater than 100 microns, preferably less than 25 microns, constitute 0.01-20% by weight of the composition and desirably be insoluble in the surface-active agent-propellant mixture.  Many medicines are specified as powders.  Particularly for water-soluble powders the moisture content of the composition should be less than 300 parts per million by weight.  The propellant is preferably a fluorinated or fluorochlorinated alkane containing not more than two carbon atoms and at least one fluorine atom, i.e. a "Freon."  Other propellants are named. The surface-active agent should be preferably soluble in the propellant and constitute 0.1-20% by weight of the composition and have a hydrophile-lipophile balance (HLB) ratio of less than 10, preferably 1-5.  Many surface-active agents are named, the sorbitan oleates being preferred.  An anhydrous non-reactive desiccant, e.g. silica gel, may be incorporated in the composition.  The specific gravity of the powder should be at least as great as the specific gravity of the propellant, and where the specific gravity of the medicinal ingredient is less than the specific gravity of the propellant an auxiliary solid (several specified) should be added.  A formula is provided for the minimum amount of auxiliary solid required in such cases. The amount of auxiliary solid employed should be 1-10, preferably 1-3, times this minimum.
A waitlist control is included to compare the treatment conditions to a no-treatment condition and serves as a control for the effects of time and assessment on efficacy. Participants in the waitlist condition will be instructed to wait 14 weeks. After the 14-week period, participants will be offered iCBT treatment with planned therapist feedback and with elective modules. If participants do not wish to receive the iCBT treatment, they will receive help in finding another relevant treatment if needed.
OBJECTIVE: Utilizing biological scaffolds for cartilage tissue engineering is a promising tool for improving auricular reconstruction. Decellularized auricular scaffolds provide a means of regenerating cartilage for in vivo implantation, but identifying the ideal regenerative mix remains challenging.
METHODS: Human cadaver auricular cartilage was decellularized and recellularized with either auricular chondrocytes alone, auricular chondrocytes with adipose-derived stem cells, or both cells with platelet-rich plasma. Confirmation of decellularization and recellularization was done by hematoxylin and eosin staining. Extracellular matrix preservation and production were determined by Masson's trichrome, Alcian blue, and Verhoeff-van Gieson staining. Collagen II assessments were made using immunohistochemistry.
RESULTS: Decellularization of cadaver auricular cartilage was confirmed by the absence of cells, reduction in glycosaminoglycans, and the preservation of collagen and elastin. Recellularization was more efficient when chondrocytes were seeded with adipose-derived stem cells, which was enhanced by adding platelet-rich plasma. Coculture with platelet-rich plasma yielded better total collagen (56% increase) and glycosaminoglycan (47% increase) induction. Moreover, when platelet-rich plasma was added, collagen II induction was significantly increased (42%; P < 0.05).
CONCLUSION: We identified a regenerative protocol that included auricular chondrocytes, adipose-derived stem cells, and platelet-rich plasma, which stimulated chondrogenesis on decellularized auricular cartilage. This finding provides a model to explore cartilage formation and the potential for improving auricular and cartilage-based reconstruction.
A 73-year-old woman having a throat lump sensation and dysphagia for the past several months presented at our otorhinolaryngology outpatient clinic. A physical examination disclosed a protruding subepithelial mass over the right tonsil fossa. The mass was not tender and had no mucosal lesions or signs of active infection. Therefore, we arranged face and neck computed tomography scans, which reported a solitary osseous lesion over the anterior-right aspect of the C1-2 joint. Considering the rarity and unfamiliar anatomy of this disease, we built a 3D-printed model to assist with the surgical rehearsal of the procedure as well as with a preoperation discussion with the patient and her family. We arranged a combined Otolaryngology-Neurosurgery department approach after discussion with the neurosurgeon and successfully removed the lesion without sacrificing the overlying longus capitis muscle. The pathology examination revealed no evidence of malignancy. The final diagnosis was cervical spine solitary osteochondroma. The patient had a complete recovery of both oral cavity and normal swallowing function. No tumor recurred during the 3-year follow-up. On the basis of this case, in-house 3D-printing technology can offer a rapid, reliable model for an interdisciplinary team to use to enhance personalized presurgical planning, thus providing better patient engagement during hospitalization.
The invention relates to a traditional Chinese medicine for treating breast hyperplasia and breast cancer. The traditional Chinese medicine can be used for effectively solving the treatment medicinal problems of the breast hyperplasia and breast cancer. The technical scheme for solving the problems is as follows: the traditional Chinese medicine is prepared from radix curcumae processed with vinegar, trigone processed with vinegar, rhizoma zedoariae processed with vinegar, processed pangolin, seaweed, iphigenia indica, radix codonopsitis, astragalus root, fruit of glossy privet, honeysuckle, lithospermum, chrysanthemum, rhizoma cyper processed with vinegar, trichosanthes, rubia root, corydalis tuber processed with vinegar, uniflower swisscentaury root, rhizoma coptidis, processed vomiting nut, chilopod, rheum officinale, fried cowherb seed, fried mustard seed, tangerine seed, prepared frankincense, prepared myrrh, oarweed and paris polyphylla. The material medicines are crushed and prepared into pills by using water and dried, respectively. The material medicines are effectively combined and supported with each other to achieve the effects of detoxicating and resolving a mass, tonifying qi and dredging collaterals, and promoting blood circulation to remove blood stasis. Besides, the traditional Chinese medicine is effectively used for treating the breast hyperplasia and breast cancer, and is safe in medicine use, good in curative effect and innovative on medicines for treating the breast hyperplasia and breast cancer.
FIELD: medicine. SUBSTANCE: the suggested pharmaceutical preparation contains, at least, active substance and carrier as particles chosen out of group including liposomes, microspheres, nanoparticles. The present innovation , also, deals with prophylaxis or treatment of human or animal infectious diseases of throat, nose and ears. The suggested preparations are povidon-iodine to prepare pharmaceutical composition for treating diseases of superior respiratory pathways and/or ear being susceptible to injection of such substances. Innovation provides delayed release of medicinal preparations and prolonged local action of active substance in superior respiratory pathways. EFFECT: higher efficiency. 23 cl, 1 tbl
PCT No. PCT/SE91/00839 Sec. 371 Date Jun. 7, 1993 Sec. 102(e) Date Jun. 7, 1993 PCT Filed Dec. 5, 1991 PCT Pub. No. WO92/10195 PCT Pub. Date Jun. 25, 1992.A cell proliferation matrix consisting of an aqueous gel of hyaluronic acid or a pharmaceutically acceptable salt thereof which is free from production-related animal DNA and RNA and which is in a dissolved state, is disclosed. Further, the use of hyaluronic acid or a pharmaceutically acceptable salt thereof for the preparation of a cell proliferation matrix according to the invention, for the treatment of at least one of bone fractures, Ulcus Varicosum Cruris, and ulcera caused by Diabetes Mellitus and other diseases (e.g. Decubitus) with impaired arterial blood flow, is described. Also, a method of treating at least one of bone fractures, Ulcus Varicosum Cruris, and ulcera caused by Diabetes Mellitus and other diseases with impaired arterial blood flow is disclosed.
Disclosed is a method for modification of heat resistance of Newcastle disease virus and use thereof, according to which heat resistance of Newcastle disease virus can be distinctly improved through replacement of HN genes. The present disclosure takes advantage of reverse genetic manipulation technique. Modification of non-heat-resistant Newcastle disease virus is based on modification of transcription plasmid, which is achieved through replacing a HN gene of a non-heat-resistant Newcastle disease virus with a HN gene of a heat-resistant Newcastle disease virus. The modified transcription plasmid is used to transfect a host cell. A recombinant Newcastle disease virus is rescued and obtained. The recombinant Newcastle disease virus has a distinctly improved heat resistance. The present disclosure, for the first time, enormously improves the heat resistance characteristic of Newcastle disease virus through artificial recombinant, and successfully transforms the non-heat-resistant Newcastle disease vaccine LaSota strain into a heat-resistant Newcastle disease vaccines rT-HN strain. The method provided by the present disclosure can be widely used in modification of heat resistance of Newcastle disease virus strains, and has a broad application prospect in developing heat-resistant, safe, and efficient Newcastle disease vaccines.
Understanding the molecular mechanisms of complex traits is essential for developing targeted interventions. We analyzed liver expression quantitative-trait locus (eQTL) meta-analysis data on 1,183 participants to identify conditionally distinct signals. We found 9,013 eQTL signals for 6,564 genes; 23% of eGenes had two signals, and 6% had three or more signals. We then integrated the eQTL results with data from 29 cardiometabolic genome-wide association study (GWAS) traits and identified 1,582 GWAS-eQTL colocalizations for 747 eGenes. Non-primary eQTL signals accounted for 17% of all colocalizations. Isolating signals by conditional analysis prior to coloc resulted in 37% more colocalizations than using marginal eQTL and GWAS data, highlighting the importance of signal isolation. Isolating signals also led to stronger evidence of colocalization: among 343 eQTL-GWAS signal pairs in multi-signal regions, analyses that isolated the signals of interest resulted in higher posterior probability of colocalization for 41% of tests. Leveraging allelic heterogeneity, we predicted causal effects of gene expression on liver traits for four genes. To predict functional variants and regulatory elements, we colocalized eQTL with liver chromatin accessibility QTL (caQTL) and found 391 colocalizations, including 73 with non-primary eQTL signals and 60 eQTL signals that colocalized with both a caQTL and a GWAS signal. Finally, we used publicly available massively parallel reporter assays in HepG2 to highlight 14 eQTL signals that include at least one expression-modulating variant. This multi-faceted approach to unraveling the genetic underpinnings of liver-related traits could lead to therapeutic development.
Cohort includes pregnant women not exposed to SPIKEVAX or any other COVID-19 vaccine within 60 days prior to LMP through the exposure ascertainment period for the outcome of interest. These women also had at least one medically attended COVID-19 episode during the exposure ascertainment period outcome of interest.
Patients with inflammatory bowel disease who undergo abdominopelvic intestinal surgery are at increased risk for developing venous thromboembolism, in the form of deep vein thrombosis, pulmonary embolism and mesenteric vein thrombosis for 90-days after surgery. Despite being high-risk, the standard of care is to provide mechanical and chemoprophylaxis (unfractionated heparin or low molecular weight heparin) only while they are hospitalized. There exists randomized data, in patients who have had surgery for abdominopelvic cancer, confirming the efficacy of extended post-discharge chemoprophylaxis with either unfractionated heparin or low molecular weight heparin for 28 days after surgery, but no such data exists for IBD. There has been a resistance to adopting this for IBD patients due to compliance and cost of the daily injections. However, recently, a large, multicenter, randomized trial in \>3000 patients who underwent total hip or total knee replacement found that extended aspirin (81 mg) twice daily post-discharge was both equivalent and non-inferior to prophylaxis using full-strength anticoagulation with a factor Xa inhibitor. This is a prospective, multicenter, open label clinical trial to assess the safety and efficacy of post-operative venous thromboembolism (VTE) prophylaxis with aspirin 81 mg orally twice daily for 30-days after surgery for IBD compared with controls receiving standard of care.
Emotional disorders (EDs;including anxiety disorders, unipolar mood disorders, and related disorders) are the most prevalent mental disorders in the general population. In Spain, anxiety disorders and mood disorders affect approximately two million (4.1%) and two and half million (5.2%) individuals, respectively. As a result of their prevalence in the society, EDs have become an alarming health problem due to their associate costs. These disorders have a direct cost of 22.000 million euros (500 euros per capita and year). The total expense of these disorders entails 2.2% of the Gross Domestic Product in Spain. Due to the excessive demand for treatment, mental health services of our National Health System (NHS) are collapsed with large waiting lists, which results in a great difficulty to dedicate the recommended time to attend patients who require psychological treatment. Therefore, it is needed to find solutions for the effective and cost-effective treatment of EDs in our NHS. In the last years, several solutions have been proposed to alleviate this important health problem.

The general objective of this project is to contribute to the dissemination of evidence-based psychological treatments in our Public National Health System for the most prevalent mental disorders in our society, emotional disorders (EDs). The investigators will study the efficacy, cost-effectiveness, and implementation characteristics (acceptability, usability, and utility) of a blended intervention which will enhance face-to-face treatment by incorporating an app-based intervention onsite treatment. Based on the most recent clinical advances in the treatment of EDs, the investigators will use the Unified Protocol (UP) for transdiagnostic treatment of EDs in the blended intervention (UP-APP). The investigators hypothesize that the blended intervention will be superior to the treatment as usual (face-to-face, specific-disorder treatment) because patients in the UP-APP condition will continue working with the app at home between sessions. In sum, this project is composed of three connected studies: a validation study in a clinical sample of patients with EDs, two pilot studies to help develop the app based on the UP principles, and a multicenter, randomized and controlled clinical trial that will be conducted by 12 clinical psychologist working in 8 different provinces in Spain.
The invention discloses a preparation method of a sedative hypnotic pharmaceutical preparation. The preparation method includes the steps of dissolving active ingredient dexzopiclone or zopiclone in acidifier-containing acidic solution to give drug-containing acidic solution, and then performing wet granulation with the obtained drug-containing acidic solution, basifier and adjuvant. The acidifier is hydrochloric acid, and the basifier is sodium hydroxide. One or more of organic weak acid, acid salt and conjugate base of organic weak acid are added before or during the addition of the basifier. The invention also discloses the sedative hypnotic pharmaceutical preparation prepared by the method. The inventive preparation method has no potential safety hazard, simple and convenient operation, low pollution and loss, low cost, and good process controllability. The obtained pharmaceutical preparation has excellent dissolution and stability, and lower related substance content.
The present invention provides methods for high level, regulated transgene transcription that is restricted to cell populations of specific types. The process is designed to work with any inducible expression regulation systems, adapting them to a tissue-specific expression pattern while simultaneously delivering maximal achievable expression levels. In particular, the invention utilizes hybrid promoters that contain the DNA elements for both cell type-specific and regulated transcription. By placing the gene of the transcriptional activation factor (TAF) under the control of this tissue-specific/drug-regulated (TSDR) promoter, this invention achieves high expression levels of TAF in specific target cells by first initiating TAF  expression using cell-type specific transcription elements, and subsequently amplifying transcriptional activity by establishing an autoregulatory positive feedback loop. In non-target cells, cell type-specific elements of the TSDR  promoter will be inactive, the TAF expression will not be initiated, and auto-regulation will not occur. For cell type-specifc promoters with leaky low-level activity in non-target cells, a variation of this system has been developed which combines autologous upregulation of TAF with the expression of cross-competing transcriptional silencers (TSi) to achieve a type of eukaryotic ~gene switch~ - either shutting off transgene and TAF expression completely or promoting maximal expression levels.
Elevated Liver Enzymes 

Daysee is contraindicated in women with acute viral hepatitis or severe (decompensated) cirrhosis of the liver [see Contraindications (4)]. Acute liver test abnormalities may necessitate the discontinuation of Daysee until the liver tests return to normal and Daysee causation has been excluded. Discontinue Daysee if jaundice develops.

Liver Tumors

Daysee is contraindicated in women with benign or malignant liver tumors [see Contraindications (4)]. COCs increase the risk of hepatic adenomas. An estimate of the attributable risk is 3.3 cases/100,000 COC users. Rupture of hepatic adenomas may cause death from abdominal hemorrhage.

Studies have shown an increased risk of developing hepatocellular carcinoma in long-term (> 8 years) COC users. The attributable risk of liver cancers in COC users is less than one case per million users.
The utility model discloses a dual red soft capsule. The soft capsule is composed of a layer of soft capsule skin 1 and an enwrapped soft capsule content 2. The enwrapped soft capsule content 2 is in extractum shape, comprising extracts and supplementary materials taken from the roots of red rooted salvia and tree peony bark. The utility model is changed from the formulation of dual red grease, which is provided with the efficacy of stimulating circulation to end stasis and dredging channels and alleviating pain. After the formulation of soft capsule is disintegrated, the utility model is directly absorbed by intestine, gone without dissolving process. The utility model can be absorbed rapidly and its content is accurate; and the biological utilizing extent is high; functional substance is good in stability and it is not prone to absorb dampness,  good in sealing to shelter unsound odors of the medicine, convenient for taking with beautiful outline and popular with the people.
PURPOSE: To obtain a resistance conquering agent comprising a prescribed compound and/or its salt, useful for chemotherapy of cancers and infectious diseases because of its excellent resistance conquering action on resistant cancers and resistant pathogenic microorganisms. CONSTITUTION: This resistance conquering agent comprises a compound of the formula (R is amino or a substitutable phenylmethylazo which may contain an N atom in a ring) and/or its salt as an active ingredient. 1-Amino-4- dibenzosuberylpiperazine, etc., are preferable as the compound of the formula. The compound, for example, is obtained by reacting dibenzosuberyl chloride with nitronsopiperazine in an organic solvent in the presence of an alkali under heating and reducing the reaction product. Hydrochloride of the compound of the formula is preferable as the salt of the compound of the formula. A daily dose of the objective agent is preferably 10-500mg/adult.
Myosotis essential oil is composed of, by mass, 26-39 parts of myosotis, 14-24 parts of olive oil, 21-31 parts of radix angelicae, 45-60 parts of mint leaves, 4-9 parts of aloe, 23-38 parts of vegetable shortening, 8-14 parts of coconut oil, 3-5 parts of fructus lycii and 12-17 parts of leonurus japonicas. The raw materials are weighed according to the mass parts, and the myosotis is cleaned, cut up and air-cooled with cold air for standby application. The vegetable shortening, the coconut oil and the olive oil are mixed, heated to 67 DEG C and subjected to heat preservation for one hour to obtain mixed essential oil. The radix angelicae, the mint leaves, the aloe, the fructus lycii and the leonurus japonicas are cut up and placed into the mixed essential oil, and the mixed essential oil is stirred and heated to 89 DEG C at the same time, subjected to heat preservation for three hours and then cooled to the room temperature. The standby myosotis is placed into the mixed essential oil and subjected to ultrasonic high-speed dispersion, obtained essential oil is filtered, filter residues are removed, and thus the finished myosotis essential oil is obtained. The myosotis essential oil has the advantages of being capable of beautifying and whitening bodies, clearing away the heat and improving the eyesight, and having a certain eliminating effect on freckles and acne.
There is consistent evidence from observational studies that higher amounts of body fat are associated with increased risks of cancer. Many behavioral weight loss interventions have been developed, but still have significant limitations in terms of achieving clinically significant, sustained weight loss. A recent study incorporating Acceptance and Commitment Therapy (ACT) in a randomized clinical trial resulted in participants who attained significantly greater 12-month weight loss in the ACT arm than those assigned to standard behavioral treatment, suggesting that ACT may have the potential to improve behavioral weight loss outcomes. However, this study required in-person clinic visits with treatment groups, which limits its potential reach and disseminability. The investigators have developed a novel telephone-delivered version of the ACT behavioral weight loss intervention, based on our proven success using ACT telephone counseling intervention for smoking cessation. There will be a two-arm pilot randomized trial (N = 100), comparing the ACT telephone intervention to a standard behavioral treatment (SBT) telephone control. The pilot RCT will yield engagement, receptivity, and preliminary weight loss results that will provide critical and timely weight loss intervention data.